{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreieugjhmxttjd74qda53bd4enheudd6wzlocgnjzcrr3jutadwe2pe",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mlcpb3hscq42"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreig3jat5bl2hi3aoatr6dsiul54sujqlg4cu4qdgn6j2y7a7d5tvyy"
    },
    "mimeType": "image/jpeg",
    "size": 144311
  },
  "path": "/2026/05/07/fda-reconsider-rare-disease-drug-ebvallo/?utm_campaign=rss",
  "publishedAt": "2026-05-07T12:00:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Breaking News",
    "Pharma",
    "Politics",
    "biotechnology",
    "Cancer",
    "drug development",
    "FDA",
    "Pharmaceuticals",
    "STAT+"
  ],
  "textContent": "The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.",
  "title": "STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection",
  "updatedAt": "2026-05-07T00:21:09.000Z"
}